Corrigendum: Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins.

[This corrects the article on p. 394 in vol. 7, PMID: 27766096.].

In the original article, there was an error [wrong description on LY3164530 (Eli Lilly) antibody in the last paragraph of page 9 of original article].

A correction has been made to section “HETERODIMERIC Fc-BASED ANTIBODIES IN DIVERSE FORMATS”, subsection “Intact IgG Formats with Correct LC Association”, sixth Paragraph (line 8–12 of the sixth paragraph) (In the last paragraph of page 9 of original article):

An alternative approach for enforcing correct HCVH-CH1–LC association includes introduction of a set of mutations at the heterodimeric VL–CL and VH–CH1 interface (18, 66, 67), similar to modification of the CH3 interface for the heterodimeric Fc design. In an ortho-Fab IgG approach (18), structure-based regional design introduced complementary mutations at the LC and HCVH-CH1 interface in only one Fab, without any changes being made to the other Fab (Figure 3). Zymeworks is currently developing intact IgG-format bsAbs generated by the combination of ortho-Fab IgG and ZW1 Fc technologies (http://www.zymeworks.com/).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.